Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, including stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Opsumit shows real-world safety, efficacy for CTD-PAH patients

Most people with pulmonary arterial hypertension (PAH) due to connective tissue disease (CTD) who are using Opsumit (macitenan) do so as part of a combination therapy, according to real-world evidence from two U.S. drug registry studies. Its safety and effectiveness, in terms of clinical outcomes, for these patients…

PH raises risk of severe cardiac, respiratory issues in HIV patients

Having pulmonary hypertension (PH) worsens the likelihood of potentially life-threatening cardiac and respiratory complications in people with human immunodeficiency virus (HIV) infection, a U.S. database study reported. Its findings “can inform clinical practice and help healthcare providers make more informed decisions regarding the screening, diagnosis, and management of PH…

MicroRNA levels may help predict CTEPH diagnosis: Study

Blood levels of microRNA — small RNA molecules that regulate protein production — are decreased in people with pulmonary embolism (PE) compared with healthy people. PE is the cause of chronic thromboembolic pulmonary hypertension (CTEPH). However, higher blood levels of miR-let7a were found in people with acute PE who…

Men with PAH have higher mortality, despite better measures

Despite having more favorable clinical measures, such as blood flow, men with pulmonary arterial hypertension (PAH) have a higher mortality risk than women with the disease, according to a recent study. This is known as the “sex paradox” and may occur because men may develop PAH only if higher…

Gradient enrolls 1st patient in study of ultrasound-based catheter device

Gradient Denervation Technologies has enrolled the first patient in a clinical study of an ultrasound-based catheter device for the treatment of pulmonary hypertension (PH) caused by left heart disease. The PreVail-PH2 (NCT06052072) study is evaluating the feasibility of the minimally invasive device in delivering therapeutic ultrasound energy…

Tenax acquires global rights to oral, subcutaneous levosimendan

Tenax Therapeutics has secured global rights to oral and subcutaneous (under the skin) formulations of levosimendan, a potential therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Under a licensing agreement established with Orion Corp. in 2013, Tenax acquired developmental and commercial rights of…

1st human trial of ZMA001 for PAH starts to dose healthy adults

The first healthy volunteer has been dosed in a Phase 1 trial testing ZMA001, Zymedi’s first-in-class investigational therapy for pulmonary arterial hypertension (PAH). The trial (NCT05967299), still recruiting participants at a clinical center in Bethesda, Maryland, will evaluate the safety, tolerability, and pharmacological properties of ZMA001.

Pulmonary rehab sites more than an hour away for US rural residents

Access to pulmonary rehabilitation programs for people with pulmonary hypertension (PH) and other chronic respiratory conditions is considerably more difficult for those living in rural U.S. regions than in urban areas, scientists report. Travel longer than 60 minutes affects more than 14 million U.S. residents of rural or underpopulated…

Cereno awarded compassionate use of CS1 for PAH

The U.S. Food and Drug Administration (FDA) has approved Cereno Scientific’s investigational drug CS1 in an extension of the ongoing Phase 2 clinical trial testing it in people with pulmonary arterial hypertension (PAH). This expanded access is sometimes called compassionate use. The…

Heart condition in PH tied to worst hospitalization outcomes in study

Atrial fibrillation or AF — a heart condition marked by an irregular heartbeat — is associated with longer hospital stays, higher inpatient mortality, and greater hospitalization costs in patients with pulmonary hypertension (PH), according to a new large-scale study. The findings indicate that this heart condition, common in people…

Survey reveals patients’ preferences for treating PAH

When choosing a treatment regimen, people with pulmonary arterial hypertension (PAH) consider the impact on physical limitations and survival at three years as the most important parameters to consider, according to a study in Germany. Meanwhile, unplanned hospitalizations within three years and short-term side effects were reported as less…